Skip to main content
SpringerLink
Log in

Somatostatin receptor expression in adrenocortical tumors and effect of a new somatostatin analog SOM230 on hormone secretion in vitro and in ex vivo adrenal cells

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background: Somatostatin is a widely distributed polypeptide that modulates endocrine and exocrine secretion, cell proliferation, and apoptosis by 5 somatostatin receptors (SSTR1–5). The inhibitory effects of somatostatin on tumor growth may be the result of its suppressing the synthesis and/or secretion of growth factors and growth-promoting hormones. Aim: Very little information is available on the effect of somatostatin analogs on adrenal tumors, so we examined SSTR expression in adrenocortical tumors and studied the effect of a somatostatin analog (SOM230) on hormone secretion and cell viability in adrenal cells. Material/subjects and methods: SSTR expression was analyzed by real-time PCR in 13 adrenocortical carcinomas (ACC), 24 aldosterone-producing adenomas (APA), 11 cortisol-producing adenomas (CPA), and 7 normal adrenals (NA), and verified by immunohistochemistry (IHC) in 14 samples. The effect of SOM230 on cortisol or aldosterone secretion in H295R and primary cell cultures was determined by radioimmunoassay, and its effect on viability in H295R and SW13 using the MTT test. Results: SSTR1 and SSTR2 mRNA was expressed in 100% of adrenal tumors. Compared to NA, ACC revealed an increase in almost all SSTR, while only some APA over-expressed SSTR3 and SSTR1. CPA expressed SSTR similar to NA. IHC confirmed the mRNA expression data. At nanomolar concentrations, SOM230 inhibited hormone secretion in primary adrenal cultures and H295R cells, but had no evident effect on cell viability. Conclusions: The evidence of SSTR over-expression (particularly in ACC) and of hormone secretion being inhibited by SOM230 suggests a potential therapeutic role for this broad-spectrum somatostatin analog in adrenal tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clin Endocrinol 2004, 60: 273–87.

    Article  Google Scholar 

  2. Reincke M. Mutations in adrenocortical tumors. Horm Metab Res 1998, 30: 447–55.

    Article  PubMed  CAS  Google Scholar 

  3. Kirschner LS. Signaling pathways in adrenocortical cancer. Ann N Y Acad Sci 2002, 968: 222–39.

    Article  PubMed  CAS  Google Scholar 

  4. Terzolo M, Pia A, Berruti A, et al. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab 2000, 85: 2234–8.

    PubMed  CAS  Google Scholar 

  5. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007, 356: 2372–80.

    Article  PubMed  CAS  Google Scholar 

  6. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999, 20: 157–98.

    Article  PubMed  CAS  Google Scholar 

  7. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006, 17: 1733–42.

    Article  PubMed  CAS  Google Scholar 

  8. Grozinsky-Glasberg S, Grossman AB, Korbonits M. The role of somatostatin analogues in the treatment of neuroendocrine tumours. Mol Cell Endocrinol 2008, 286: 238–50.

    Article  PubMed  CAS  Google Scholar 

  9. Pandha HS, Harrington K, Saini S, Lynn J, Peters M, Waxman J. Secretory symptoms from metastatic adrenal cortical carcinoma responding to octreotide. Postgrad Med J 1995, 71: 229–30.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  10. Chan NN, Isaacs AJ. Lack of response to octreotide in Cushing’s syndrome due to metastatic adrenocortical carcinoma. Postgrad Med J 1999, 75: 96–7.

    PubMed Central  PubMed  CAS  Google Scholar 

  11. Florio T, Thellung S, Arena S. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur J Endocrinol 1999, 141: 396–408.

    Article  PubMed  CAS  Google Scholar 

  12. Cheung NW, Boyages SC. Somatostatin-14 and its analog octreotide exert a cytostatic effect on GH3 rat pituitary tumor cell proliferation via a transient G0/G1 cell cycle block. Endocrinology 1995, 136: 4174–81.

    PubMed  CAS  Google Scholar 

  13. Bevan JS. The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005, 90: 1856–63.

    Article  PubMed  CAS  Google Scholar 

  14. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002, 146: 707–16.

    Article  PubMed  CAS  Google Scholar 

  15. Murray RD, Kim K, Ren SG, et al. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab 2004, 89: 3027–32.

    Article  PubMed  CAS  Google Scholar 

  16. Hofland LJ, van der Hoek J, Feelders R, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005, 152: 645–54.

    Article  PubMed  CAS  Google Scholar 

  17. Pasquali D, Rossi V, Conzo G, et al. Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells. J Mol Endocrinol 2008, 40: 263–71.

    PubMed  CAS  Google Scholar 

  18. Bruno JF, Xu Y, Song J, Berelowitz M. Tissue distribution of somatostatin receptor subtype messenger ribonucleic acid in the rat. Endocrinology 1993, 133: 2561–7.

    PubMed  CAS  Google Scholar 

  19. Ueberberg B, Tourne H, Redman A, et al. Differential expression of the human somatostatin receptor subtypes sst1 to sst5 in various adrenal tumors and normal adrenal gland. Horm Metab Res 2005, 37: 722–8.

    Article  PubMed  CAS  Google Scholar 

  20. Unger N, Serdink L, Sheu SY, et al. Immunohistochemical determination of somatostatin receptor subtypes 1, 2A, 3, 4 and 5 in various adrenal tumors. Endocr Res 2004, 30: 931–4.

    Article  PubMed  CAS  Google Scholar 

  21. Unger N, Serdiuk I, Sheu SY, et al. Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumors. Clin Endocrinol (Oxf) 2008, 68: 850–7.

    Article  Google Scholar 

  22. Pisarek H, Stepien T, Kubiak R, Pawlikowski M. Somatostatin receptors in human adrenal gland tumors-immunohistochemical study. Folia Histochem Cytobiol 2008, 46: 345–51.

    Article  PubMed  Google Scholar 

  23. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989, 13: 202–6.

    Article  PubMed  CAS  Google Scholar 

  24. MacFarlane DA. Cancer of the adrenal cortex: the natural history, prognosis and treatment in the study of fifty-five cases. Ann R Coll Surg Engl 1958, 23: 155–86.

    PubMed Central  PubMed  CAS  Google Scholar 

  25. Sullivan M, Boileau M, Hodges CV. Adrenal cortical carcinoma. J Urol 1978, 120: 660–5.

    PubMed  CAS  Google Scholar 

  26. Pagès P, Benali N, Saint-Laurent N, et al. Sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. J Biol Chem 1999, 274: 15186–93.

    Google Scholar 

  27. Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996, 10: 1688–96.

    PubMed  CAS  Google Scholar 

  28. Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci 2008, 13: 822–40.

    Article  PubMed  CAS  Google Scholar 

  29. Florio T, Morini M, Villa V, et al. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 2003, 144: 1574–84.

    Article  PubMed  CAS  Google Scholar 

  30. Hofland LJ. Somatostatin and somatostatin receptors in Cushing’s disease. Mol Cell Endocrinol 2008, 286: 199–205.

    Article  PubMed  CAS  Google Scholar 

  31. McDermott JH, Thabit H, Hickey N, et al. ACTH-secreting bronchial carcinoid: a diagnostic and therapeutic challenge. Ir J Med Sci 2008, 177: 269–72.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology Division, Italy

    B. Mariniello PhD, I. Finco, P. Sartorato, A. Patalano & F. Mantero

  2. Endocrine Surgery Division, Department of Medical and Surgical Sciences, Italy

    M. Iacobone

  3. Pathology Section, Department of Diagnostic Medical Sciences and Special Therapies, University of Padua, Padua, Italy

    V. Guzzardo & A. Fassina

Authors
  1. B. Mariniello PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Finco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Sartorato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Patalano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Iacobone
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V. Guzzardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Fassina
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F. Mantero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Mariniello PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mariniello, B., Finco, I., Sartorato, P. et al. Somatostatin receptor expression in adrenocortical tumors and effect of a new somatostatin analog SOM230 on hormone secretion in vitro and in ex vivo adrenal cells. J Endocrinol Invest 34, e131–e138 (2011). https://doi.org/10.1007/BF03346721

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03346721

Key-words

Search

Navigation